Page 29 - ITPS-8-1
P. 29

INNOSC Theranostics and
            Pharmacological Sciences                                              Transcriptome-based RNA sequencing




            Table 2. (Continued)
            S. No. Purpose         Study pattern  Sample type  Methodology       Justification  Year of  References
                                                                                                study
            8    The most prevalent   The aim of this study   Synovium  The study used the   A total of 206 genes with   2021  53
                 internal alteration   was to identify different   MH7A cell line to detect   differentially regulated
                 found in eukaryotic  amounts of m6A       m6A methylation in RA,   m6A methylation were
                 mRNAs is      methylation in human        confirming the expression  detected using m6A-
                 N6-methyladenosine  RA using two high-    levels in MH7A cells and   seq, of which 118 had
                 (m6A), and it exerts  throughput sequencing   synovial tissues of AA rats. substantially elevated m6A
                 a direct effect on the  techniques.                         methylation and 88 had
                 development and                                             significantly decreased
                 course of several                                           m6A methylation.
                 diseases, particularly                                      In MH7A cells, the
                 tumors. This study                                          transcriptional mapping
                 investigated the                                            of m6A was performed,
                 relationship between                                        and a possible correlation
                 m6A methylation                                             between the RNA
                 and RA using                                                methylation alteration
                 transcriptomic                                              and RA-related genes was
                 RNA-seq.                                                    noted.
            Abbreviations: RNA-seq: RNA sequencing; RA: Rheumatoid arthritis.

            poor quality. To identify the differentially expressed genes   with MTX being the first-line treatment in 40 – 60% of
            (DEGs) based on fold change and statistical significance   cases. 35,36
            criteria, techniques such as DEseq2 and limma-voom
            are used. Moreover, it performs DEG annotation using   3.5. Immune dysregulation
            databases and bioinformatics tools, and DEG maps are   Analyzing gene expression in immune cells and the
            used to identify pathways that are enriched in dysregulated   synovium can assist in identifying dysregulated pathways
            genes according to predetermined criteria. Bar plots,   and RA etiology using RNA sequencing. The expression
            bubble  plots,  and  network  diagrams  are  useful  for   patterns of cytokines and chemokines in the synovium and
            showing the most important pathways. 33,34  Dysregulated   other tissues of patients with RA were also examined. Tumor
            pathways in RA include T-cell receptor signaling, altered   necrosis factor-alpha, interleukin-6, and other chemokines
            B-cell receptor signaling, autoantibodies, and the Toll-  can be used to identify the pathophysiology of RA. RNA-
            like receptor. Type  I  IFN signaling is activated  in RA,   seq enables the profiling of autoantigens, immunological
            contributing to inflammation and joint destruction. The   tolerance, and autoantibodies. Autoimmune problems are
            signal transducer and activator of transcription (STAT)   significant for patients with RA. Combining all omics data
            regulates  inflammation  and  the  immune  response,   helps in the study of immune dysregulation (genomics and
            whereas nuclear factor-κB regulates gene expression.   proteomics). 37-39
            Abnormal expression of the Janus kinase–STAT pathway
            and the mitogen-activated protein kinase (MAPK) signal   4. Transcriptomic profiling of synovial
            transduction pathway also contribute to RA pathogenesis.  tissue and fluid in patients with RA

            3.4. Personalized medicine                         The synovium, a thin tissue layer,  aids  in the function
                                                                                                            40
                                                               of diarthrodial joints by lining the fibrous capsule.
            The traditional treatment for RA involves medication,
            psychotherapy, and rehabilitation to maintain the   In healthy joints, it generates lubricin and hyaluronate
                                                               for synovial fluid, supporting flexion and load-bearing
            locomotor system and reduce discomfort, inflammation,   without compromising bone and cartilage integrity. The
            and osteoporosis. Weak opioids, muscle relaxants, and
            analgesics are used to manage pain, whereas strong opioids   inflammatory synovium in RA exhibits tissue hyperplasia,
            such as morphine are considered in certain cases. RNA-  angiogenesis, and leukocyte infiltration, with fibroblasts
                                                               playing a vital role in cartilage destruction, leukocyte
            seq profiling can predict prognosis, treatment response,                         41
            and disease progression. Synthetic disease-modifying   influx and outflow, and bone damage.
            antirheumatic medications include cyclosporine A,    In RA, proinflammatory chemicals such as IL-6
            leflunomide,  azathioprine,  methotrexate  (MTX),  and CCL5 are generated, synovium fibroblasts are
            sulfasalazine (SSZ), and cyclophosphamide. RA is diverse,   constantly active, and matrix remodeling enzymes such


            Volume 8 Issue 1 (2025)                         23                               doi: 10.36922/itps.4449
   24   25   26   27   28   29   30   31   32   33   34